Introduction
The peroxisome proliferator-activated receptors (PPARs) are a family of ligand-activated nuclear transcription factors, consisting of three members conserved in humans and mice, PPARα, PPARδ, and PPARγ. 1 PPARα was the first PPAR cloned during an effort to identify the molecular targets of various hypolipidemic agents and peroxisome proliferator chemicals, notably the fibrate drugs, that caused pronounced peroxisome proliferation, hepatomegaly, and liver cancer in rats and mice. 2 Since then, numerous fatty acid metabolites were identified as endogenous PPARα ligands, and PPARα has been described as a principal metabolic "lipid sensor" in vivo. Upon agonist binding, PPARα forms a heterodimer with retinoid X receptor alpha and regulates target gene expression by binding to specific peroxisome proliferator response elements (PPREs) within promoter regions. As many target genes encode key enzymes involved in lipid metabolism, PPARα is considered a major transcriptional regulator of both local and systemic lipid homeostasis. 3 It is now clear that PPARα is a bona fide therapeutic target for fibrates and other synthetic hypolipidemic agents used in the treatment of hyperlipidemia. 4 Therefore, a comprehensive understanding of the physiological characteristics of PPARα activation has become essential for establishing the mechanism of regulation of dyslipidemia and related metabolic disorders, as well as determining any risks associated with offtarget effects.
Full body PPARα knockout (Ppara À/À ) mice have significantly helped in elucidating the functions of PPARα in vivo. Present evidence clearly supports a critical role for PPARα in governing fatty acid homeostasis, 5 and PPARα deficiency abolishes the normal physiological response to fasting and fibrate-induced peroxisome proliferation, hepatomegaly, and liver cancer in susceptible mammalian species. 3, [6] [7] [8] Recently, PPARα was reported to regulate bile acid homeostasis, 9 endothelial progenitor cell maturation and differentiation, 10 and even neurological functions through stimulating the expression of neurotrophin 11 or the proteolysis of amyloid precursor protein. 12 Although many studies have identified PPARα expression in non-hepatic tissues, 13, 14 there are few published studies that directly addressed the tissue-specific functions of PPARα, let alone its possible role in facilitating crosstalk between different tissues. A major reason that this has not been explored is the lack of tissue-specific Ppara knockout models.
Given that PPARα plays an important role in regulating metabolic regulation and that the liver is an essential metabolic organ 15 and a major site of PPARα expression, 14 a hepatocyte-specific PPARα knockout (Ppara ΔHep ) mouse line was developed. 16 With this mouse line, the role of hepatic PPARα in the response to Wy-14643, a potent and highly specific agonist, was examined. Evidence suggests that hepatocyte-specific PPARα activation principally facilitates the systemic lipid-lowering effects of Wy-14643.
Methods
Animals. All procedures involving mice were performed in accordance with and the approval of the National Cancer Institute Animal Care and Use Committee. C57BL/6N mice were purchased from Charles River Laboratories (Wilmington, MA, USA). Ppara wild-type (Ppara +/+ ) or Ppara-null (Ppara À/À ) mice on the C57BL/6N background were described previously. 17, 18 Ppara floxed (Ppara f/f ) or Ppara liver-specific knockout (Ppara ΔHep ) mice on the C57BL/6N background have been described. 16 repTOP PPRE-luc reporter mice were purchased from Charles River Laboratories. All mice were housed in a temperature (22°C) and light-controlled vivarium with free access to water and standard rodent chow, a standard control grain diet (vehicle grain diet), or a grain diet containing 0.1% Wy-14643 (Bio-Serv, Flemington, NJ, USA). All experiments were started on 7 to 8-week-old mice.
Wy-14643 treatment. Mice were randomly grouped to Wy-14643 (WY) grain diet or matching control vehicle grain diet (Veh). All mice were allowed unrestricted access to a diet containing 0.1% Wy-14643 (100 mg/kg/day), or control diet, respectively, for 2 days. After treatment, all mice were killed by CO 2 asphyxiation and tissues collected for analysis.
Histological staining. Fresh liver was placed into 10% phosphate-buffered formalin for 24 h to fix tissue and then processed into paraffin blocks. Sections were stained with hematoxylin and eosin. Histological sectioning was performed by HistoServ, Inc (Germantown, MD, USA). Slide imaging was performed using a Keyence BZ-X700 series all-in-one microscope with both 20× and 40× objectives, 200× and 400× magnification, respectively.
Cumulative food intake assay. Cumulative food intake was measured by indirect calorimetry in mice after being placed on a vehicle grain diet for 11 days using a 12-chamber Environment Controlled CLAMS (Columbus Instruments, Columbus, OH, USA) with one mouse/chamber as previously described. 19 After 48-h chamber acclimatization, mice were monitored for 24 h under vehicle grain diet followed by 20 h under Wy-14643 grain diet. During testing, water was provided ad libitum.
In vivo luciferase assays. repTOP PPRE-luc reporter mice were orally gavaged with vehicle (dimethylsulphoxide in 4:1 of PEG-400 and Tween 80) or Wy-14643 (50 mg/kg). Twenty-four hours following treatment, mice were dosed with 200 μL of D-luciferin (15 mg/mL DPBS, intraperitoneal). Ten minutes after D-luciferin injection, the mice were anesthetized using isoflurane and bioluminescence imaging was assessed using an IVIS Imaging System 200 Series (Xenogen, Hopkinton, MA, USA). All imaging was performed between 9 and 10 AM. The image shown is representative of each treatment. The luciferase signal was quantified using IVIS Living Imaging software (version 4.5.5) and represented as average counts after subtracting background. Four mice were imaged per treatment group.
Serum triglyceride assay. Serum triglyceride (TG) was assessed in a 96-well microplate using a commercial TG assay kit (Wako USA, Richmond, VA, USA) and monitored with a microplate reader (BioAssay Systems, Harvard, CA, USA).
Total RNA extraction, cDNA synthesis, and real-time PCR. Total RNA was extracted from frozen tissues using TRIzol reagent according to the manufacturer's instructions. The purity and concentration of total RNA samples were determined by a NanoDrop ND-1000 spectrophotometer (ThermoFisher, Waltham, MA, USA). A total of 50 ng of total RNA was reverse transcribed using cDNA Synthesis SuperMix (Biotool, Houston, TX, USA). Real-time polymerase chain reaction (PCR) was carried out in an ABI 7900HT Fast Real-Time PCR System (AB Applied Biosystems, Warrington, UK) with SYBR Green PCR master mix (AB Applied Biosystems, Warrington, UK) and gene-specific primers. The sequences for the forward and reverse primers used to quantify mRNA are available listed in Table S1 . The following conditions were used for real-time PCR: 95°C for 5 min, then 95°C for 15 s and 60°C for 1 min and 40 cycles. The 2 ÀΔΔCT method 20 was used to analyze the relative changes in gene expression normalized against 18S rRNA expression.
Statistical analysis. All results are expressed as means ± SEM. Significance was determined by (multiple) two-tailed unpaired t-test using Prism 7.0 software (GraphPad Software, San Diego, CA, USA). A P value of < 0.05 was considered significant.
Results
Wy-14643 treatment principally activates hepatic PPARα. Peroxisome proliferator-activated receptor alpha activation was assessed in live animals using mice expressing a firefly luciferase transgene under control of a PPAR response element Actionrepeat (repTOP PPRE-Luc mice). 21 Pronounced hepatic PPARα activation in response to Wy-14643 was observed (Fig. 1a) . Average luciferase counts of the treatment groups revealed a 10-fold increase in signal after Wy-14643 treatment (Fig. 1b) . This observation is consistent with the effect of Wy-14643 treatment on Ppara mRNA expression and selected PPARα target genes in brown adipose tissue (BAT), liver, kidney, and heart, the four tissues with the highest PPARα expression in mice.
14 Ppara mRNA was slightly but significantly upregulated in the liver of wild-type mice but not in heart or kidney (Fig. 1c) . Fgf21, Acadm, and Acox1 mRNAs, encoded by PPARα target genes, were upregulated in the liver with no significant induction in BAT, heart, or kidney (Fig. 1d,f,h ). Il1rap and Il15 mRNA were sharply suppressed in the liver (Fig. 1e,g ). Employing the present study conditions, it is Agonist-induced hepatomegaly is dependent on hepatocyte-specific Ppara activation. Prolonged activation of PPARα in rodents causes pronounced hepatomegaly. To determine the requirement for hepatocyte PPARα activation on hepatomegaly in response to short-term agonist treatment, Ppara wild-type (Ppara
and hepatocyte-specific Ppara knockout (Ppara ΔHep ) mice were provided either a grain diet containing 0.1% Wy-14643 or matching control diet for 2 days. Following treatment, body and liver weights were measured and liver indices calculated (mg liver/g body mass) to assess the extent of hepatomegaly (Fig. 2a) . Wy-14643 treated Ppara +/+ and Ppara f/f mice exhibited significantly higher liver indices than Ppara À/À or Ppara ΔHep mice, which were similar to controls. Liver sections were stained with hematoxylin and eosin revealing pronounced hepatocyte swelling in Ppara f/f mice treated with Wy-14643 (Fig. 2b,c) . Ppara ΔHep mice were protected from (Fig. 3a) . Serum TG levels in Ppara ΔHep mice were completely unaffected by Wy-14643 treatment and resembled that of conventional full body Ppara À/À knockout mice indicating that these effects are liverdependent (Fig. 3a) . As expected, the response of the Ppara f/f mice paralleled the Ppara +/+ mice (Fig. 3a) . In agreement with previous evidence showing that Ppara disruption prevents the upregulation of fatty acid oxidation and lipid metabolism pathways, 5 Ppara ΔHep mice exhibited undetectable levels of Ppara mRNA, lower basal expression levels of many fatty acid-metabolizing enzymes ( Fig. 3b-l) , and gene upregulation in response to agonist was abolished ( Fig. 3c-l) . These results indicate that hepatic PPARα activation is necessary for the hypolipidemic actions of PPARα agonists.
Hepatic PPARα deficiency abolishes agonistinduced appetite-suppression. Another common consequence of PPARα agonist treatment is the suppression of food intake, also known as hypophagia. [23] [24] [25] [26] In agreement with these studies, Wy-14643 significantly reduced feeding in Ppara +/+ mice (Fig. 4a) , but not Ppara À/À mice (Fig. 4b) . These results support the view that appetite suppression in this context is PPARα-dependent. Feeding behavior in animals is at least partially governed by the central nervous system, particularly the hypothalamus, 27 and oleylethanolamide, an endogenous PPARα ligand, was reported to suppress food intake mediated by the lateral hypothalamus. 28 Therefore, an emerging question has focused on whether PPARα activation in the liver, or possibly other PPARα expressing tissues, is responsible for agonist-induced appetite suppression. Considering the previous evidence, the effect of Wy-14643 on food intake was tested in Ppara f/f and Ppara ΔHep mice. Intriguingly, a decrease in food intake was only observed in Ppara f/f mice but not hepatocyte-specific Ppara ΔHep knockout mice by Wy-14643 treatment (Fig. 4c,d ). These data indicate that hepatic PPARα deficiency is sufficient to abolish the appetitesuppressing effect of Wy-14643. The underlying molecular mechanisms responsible for the crosstalk between the liver and hypothalamus after hepatic PPARα activation remains to be elucidated.
Discussion
The present studies revealed that hepatic PPARα mediates the major physiological effects of Wy-14643. PPARα agonists, namely, the fibrate class of hypolipidemic drugs, have been clinically used as for decades. However, elucidating the underlying mechanisms by which fibrates influence systemic lipid homeostasis has been an ongoing effort. Here, hepatocyte-specific PPARα activation was found to be essential for the lipid-lowering actions of Wy-14643 and likely other therapeutic drugs that target PPARα. Additionally, hepatic PPARα disruption abolished agonistinduced hepatomegaly and hypophagia. The deleterious impact of loss of hepatic PPARα on systemic lipid metabolism is logical, as the liver plays a principle role in modulating lipid catabolism and fatty acid homeostasis. 29 Hepatomegaly that results from longterm agonist treatment was recently shown to be dependent on hepatic PPARα activation, and these short-term studies strengthen support for the view that hepatocyte-specific PPARα activation plays a key role in this process. 16 Hepatic gene expression data clearly indicate that the response to Wy-14643 is abolished in Ppara ΔHep mice and that the agonist-induced metabolic pathway remodeling to promote lipid catabolism would be hindered. However, it is somewhat unexpected that the hypolipidemic effects would be solely dependent on hepatic PPARα without any apparent contribution from extrahepatic tissues. In this study, the upregulation of PPARα target genes in response to Wy-14643 was predominantly hepatic and not observed in BAT or heart. There was a slight but significant increase of Acox1 expression in the kidney. Previous studies using Wy-14643 revealed varying degrees of PPARα target gene response in extrahepatic tissues, namely, BAT, skeletal muscle, adipose tissue, and heart. [30] [31] [32] Agonist dose, route of administration, mouse age, and strain background are known to influence PPARα activity and most likely contribute to the observed inconsistencies between studies. It was also surprising that hepatic PPARα disruption would abolish hypophagia in these mice. Although many factors might affect feeding behavior, in general, peripheral signals are integrated and often compensated for by the central nervous system then transformed into a resulting physiological or behavioral change that influences food intake. 27 In this context, the current study found that (i) the hypophagic effects of Wy-14643 are liver dependent, (ii) food consumption is mediated directly by activation of PPARα within hepatocytes, and (iii) hepatic PPARα activation forms a direct or indirect signaling axis with the central nervous system. In fact, current evidence supports crosstalk between peripheral PPARα and the central nervous system in regards to feeding behavior. 24 Interestingly, a recent study found that PPARγ influenced feeding behavior through a mechanism involving signaling through the hepatic afferent vagal nerve, which can directly deliver signals to center nervous system. 33 It is therefore interesting to speculate that PPARα could use a similar mechanism to direct feeding behavior. Although the present data provide no direct evidence for a PPARα-dependent liver-brain communication axis, it provides correlative support for crosstalk between these two organ systems. Future studies will be required to clarify the mechanisms associated with hepatic PPARα-dependent control of feeding behavior and liver-neuronal satiety pathways.
In summary, the major physiological effects of Wy-14643 appear to act primarily through hepatic PPARα, and the loss of PPARα expression in the liver abolishes both local and systemic response to agonist, namely, reducing circulating lipid levels and promoting hypophagia.
